We report a memorable case of severe septal panniculitis in an MS patient following the subcutaneous administration of interferon beta-1b, manifesting as a painful, indurated, erythematous lesion of the thigh, which appeared at the injection site.
JohnsonMAKannanDGBalachandarTGJeswanthSRajendranSSurendranR. Acute septal panniculitis. A cutaneous marker of a very early stage of pancreatic panniculitis indicating acute pancreatitis. JOP2005; 6:334–8.
FrohmanEMRackeMKRaineCS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med2006; 354:942–55.
4.
JohnstonJSoTY. First-line disease-modifying therapies in paediatric multiple sclerosis: A comprehensive overview. Drugs2012; 72:1195–211.
5.
ChunJBrinkmannV. A mechanistically novel, first oral therapy for multiple sclerosis: The development of fingolimod (FTY720, Gilenya). Discov Med2011; 12:213–28.
6.
WeiseGHuppMKerstanAButtmannM. Lobular panniculitis and lipoatrophy of the thighs with interferon-ss1a for intramuscular injection in a patient with multiple sclerosis. J Clin Neurosci2012; 19:1312–3.
7.
BalakDMHengstmanGJCakmakAThioHB. Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: A systematic review. Mult Scler2012; 18:1705–17.
8.
GiovannoniGBarbarashOCasset-SemanazF. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler2009; 15:219–28.
9.
InafukuHKhanMA KasemNagataTNonakaS. Cutaneous ulcerations following subcutaneous interferon beta injection to a patient with multiple sclerosis. J Dermatol2004; 31:671–7.
10.
WebsterGFKnoblerRLLublinFDKramerEMHochmanLR. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol1996; 34:365–7.
11.
KowalzickL. Psoriasis flare caused by recombinant interferon beta injections. J Am Acad Dermatol1997; 36:501.
12.
LebrunCBertagnaMCohenM. Cutaneous side-effects of immunomodulators in MS. Int MS J2011; 17:88–94.
13.
BallNJCowanBJHashimotoSA. Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases. J Cutan Pathol2009; 36:331–7.
14.
HeinzerlingLDummerRBurgGSchmid-GrendelmeierP. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient. Eur J Dermatol2002; 12:194–7.
15.
NakamuraYKawachiYFurutaJOtsukaF. Severe local skin reactions to interferon beta–1b in multiple sclerosis-improvement by deep subcutaneous injection. Eur J Dermatol2008; 18:579–82.
16.
O'SullivanSSCroninEMSweeneyBJBourkeJFFitzgibbonJ. Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-lb in a patient with multiple sclerosis. J Neurol Neurosurg Psychiatry2006; 77:1382–3.
17.
BalakDMHengstmanGJHajdarbegovicEvan den BruleRJHuppertsRMThioFTB. Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: A cross-sectional study. BMC Neurol2013; 13:146.
18.
SoriaAMaubecEHenry-FeugeasMC. Panniculitis induced by interferon beta-1a vascular toxicity. Ann Dermatol Venereol2007; 134:374–7.
19.
OzuguzPKacarSDKaracaSTokyolC. A case of septal panniculitis secondary to interferon treatment. Cutan Ocul Toxicol. 2014 Mar 18. [Epub ahead of print]
20.
CuestaLMoragonMPerez-CrespoMOnrubiaJGarciaM. Mixed panniculitis secondary to interferon beta–1a therapy in a woman with multiple sclerosis. Actas Dermosifiliogr2013; 104:257–9.
21.
OzdenMGErelAErdemOOztasMO. Dermal fibrosis and cutaneous necrosis after recombinant interferon beta la injection in a multiple sclerosis patient. J Eur Acad Dermatol Venereol2005; 19:112–13.
ElgartGWSheremataWAhnYS. Cutaneous reactions to recombinant human interferon beta-1b: The clinical and histologic spectrum. J Am Acad Dermatol1997; 37:553–8.
24.
PachlerCIkeokaDPlankJ. Subcutaneous adipose tissue exerts proinflammatory cytokines after minimal trauma in humans. Am J Physiol Endocrinol Metab2007; 293:E690–6.
25.
ChenCChouCSunYHuangW. Tumor necrosis factor alpha-induced activation of downstream NF-kappaB site of the promoter mediates epithelial ICAM-1 expression and monocyte adhesion. Involvement of PKCalpha, tyrosine kinase, and IKK2, but not MAPKs, pathway. Cell Signal2001; 13:543–53.
26.
YangLFroioRMSciutoTEDvorakAMAlonRLuscinskasFW. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood2005; 106:584–92.
27.
FrankPGLisantiMP. ICAM-1: Role in inflammation and in the regulation of vascular permeability. Am J Physiol Heart Circ Physiol2008; 295:H926–H927.
